Anti-TNFRSF10B/TRAILR2/CD262 Antibody (Conatumumab)
Catalog No.
F1046
Anti-TNFRSF10B/TRAILR2/CD262 Antibody (Conatumumab)
Featured Products
Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for long DR5, 0.8 nM for short DR5). Conatumumab induces apoptosis by activating caspases. Conatumumab can be used in cancer research.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
145.44 kDa
Dry ice
896731-82-1
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
AMG 655, XG1-048, TRAIL-R2 mAb
100 mM Pro 20 mM Arg pH 5.0. No preservative!
O14763
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized Human TNFRSF10B/TRAILR2/CD262, Fc Tag at 2 ug/mL can bind Anti-TNFRSF10B/TRAILR2/CD262 Antibody (Conatumumab), The EC50 is 0.03101 ug/mL.
TNFRSF10B / TRAILR2 / CD262
Please avoid freeze-thaw cycles.